News from heptares therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 28, 2016, 05:05 ET Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that Dr Fiona...


Apr 25, 2016, 11:05 ET Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease

  First structure of GLP-1 receptor in active state resolved   Novel allosteric binding site in glucagon receptor identified -...


Apr 18, 2016, 03:00 ET Heptares and Kymab Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and Kymab Limited, a leading...


Apr 06, 2016, 19:30 ET Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group...


Apr 04, 2016, 07:39 ET Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has partnered...


Feb 10, 2016, 01:30 ET Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity   Heptares Therapeutics ("Heptares"), the...


Feb 02, 2016, 04:00 ET Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS)

First collaboration initiated with Imperial College London  Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group...


Nov 30, 2015, 05:00 ET Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

Heptares Therapeutics ("Heptares"), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of...


Sep 28, 2015, 03:00 ET Heptares Awarded $5.5 Million Research & Development Grant From the US National Institute on Drug Abuse (NIDA)

Project to develop first-in-class Orexin-1 receptor antagonist for the treatment of cocaine addiction and dependence. Heptares Therapeutics...


Jun 17, 2015, 02:30 ET Heptares Announces Positive Outcome of Phase 1A Study with First-ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease

Early evidence of enhanced brain activity seen at dose levels that are well tolerated  Heptares Therapeutics, the clinical-stage GPCR...


Jan 23, 2015, 04:00 ET Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm...


Jan 22, 2015, 05:00 ET Heptares Technology Enables Breakthrough in Drug Discovery Collaboration with Astrazeneca

Stable Receptor, X-ray Structure and Hit Series Generated for PAR2, a Previously Intractable Target for Pain & Inflammation  Heptares...


Jan 08, 2015, 04:00 ET Heptares Adds Experts in Drug Discovery and Development to its Board of Directors

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is pleased to announce the appointments of...


Jan 06, 2015, 04:00 ET Heptares to Present at Upcoming East/West CEO Conference

Heptares Therapeutics, the clinical-stage GPCR drug discovery and development company, notes that members of its senior management team will...


Dec 15, 2014, 04:00 ET Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce the grant of multiple key...


Nov 20, 2014, 10:16 ET Heptares Orphan Disease Programme Awarded Grant from the UK Biomedical Catalyst

  Project to develop first-in-class selective and orally available GLP-1 receptor antagonist for treating severe hypoglycaemia (low blood...


Nov 17, 2014, 04:00 ET Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch

Program to be presented at Therapeutic Area Partnerships Conference in Boston on 20 November   Heptares Therapeutics, the leading GPCR...


Sep 16, 2014, 04:00 ET Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium

Heptares Therapeutics notes that its Chief Scientific Officer, Fiona Marshall, will give a presentation entitled "Structure-based Drug Design...


Jul 07, 2014, 04:00 ET Heptares Announces Publication in Nature of First Structure of Metabotropic Glutamate Receptor 5 Transmembrane Domain

Heptares has solved structures across all major GPCR families (A, B and C) providing platforms for wide-ranging structure-based and antibody drug...


Jun 30, 2014, 04:00 ET Heptares' Chief Scientific Officer and Co-Founder Fiona Marshall to Present at Royal Society of Medicine Medical Innovations Summit

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall,...


Jun 24, 2014, 13:00 ET Heptares to Present at JMP Securities Healthcare Conference

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will...


May 29, 2014, 04:00 ET Heptares to Present at Jefferies 2014 Global Healthcare Conference and Upcoming Industry and Scientific Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief...


May 15, 2014, 04:00 ET Heptares to Present at UBS Global Healthcare Conference and Upcoming Scientific Events

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief...


Apr 16, 2014, 04:00 ET Heptares at Upcoming Diabetes and Neuroscience Partnering and Investment Conferences

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Dan Grau, Heptares' President, will be...


Mar 26, 2014, 05:00 ET Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by...